User login
Objectives: The study tests the addition of rindopepimut, an experimental cancer vaccine that targets the EGFRvIII protein, to the current standard of care. All patients receive temozolomide and are randomized to rindopepimut or a control called keyhole limpet hemocyanin (KLH). Overall survival is the primary outcome measure.
Key entry or exclusion criteria: Adult patients must have EGFRvIII-positive tumor status documented by a sponsor designated laboratory.
Locations: 149 sites
Goal: 440 patients
Study sponsor: Celldex Therapeutics
Link for more information: clinicaltrials.gov/ct2/show/NCT01480479
NIH clinical trials identifier: NCT01480479
Objectives: The study tests the addition of rindopepimut, an experimental cancer vaccine that targets the EGFRvIII protein, to the current standard of care. All patients receive temozolomide and are randomized to rindopepimut or a control called keyhole limpet hemocyanin (KLH). Overall survival is the primary outcome measure.
Key entry or exclusion criteria: Adult patients must have EGFRvIII-positive tumor status documented by a sponsor designated laboratory.
Locations: 149 sites
Goal: 440 patients
Study sponsor: Celldex Therapeutics
Link for more information: clinicaltrials.gov/ct2/show/NCT01480479
NIH clinical trials identifier: NCT01480479
Objectives: The study tests the addition of rindopepimut, an experimental cancer vaccine that targets the EGFRvIII protein, to the current standard of care. All patients receive temozolomide and are randomized to rindopepimut or a control called keyhole limpet hemocyanin (KLH). Overall survival is the primary outcome measure.
Key entry or exclusion criteria: Adult patients must have EGFRvIII-positive tumor status documented by a sponsor designated laboratory.
Locations: 149 sites
Goal: 440 patients
Study sponsor: Celldex Therapeutics
Link for more information: clinicaltrials.gov/ct2/show/NCT01480479
NIH clinical trials identifier: NCT01480479